Cell & Gene Therapy Manufacturing Services Market to hit USD 70.7 billion by 2032 at CAGR of 22.4%
The Cell & Gene Therapy Manufacturing Services Market is witnessing substantial growth, primarily driven by groundbreaking advancements in therapeutic approaches for life-threatening and rare diseases. This surge is largely attributed to the swift evolution of cell and gene therapies, which are revolutionizing the biopharmaceutical sector by enhancing clinical success rates and increasing the number of therapies in development. As of May 2022, 329 cell and gene therapies were undergoing clinical trials, with this number expected to rise significantly due to improved scientific understanding and clinical practices.